PROTOKOLwiki
COMPOUNDS / PEPTIDE / IPAMORELIN
PEPTIDE

IPAMORELIN

MEDIUM RISK
BEST FOR:Recovery●●●●●●○○○○6/10
IPAMORELIN · IPAMORELIN ACETATE · NNC 26-0161 · GHRP-LIKE PENTAPEPTIDE · AIB-HIS-D-2-NAL-D-PHE-LYS-NH2
PeptideGH SecretagogueGhrelin AgonistRecoveryWADA BannedResearch Chemical

Selective growth hormone secretagogue and ghrelin receptor agonist that stimulates GH release without affecting cortisol or ACTH levels.

ROUTE / DOSAGE
LOW500mcg
STANDARD1000-2000mcg
HIGH3000mcg+
Note: Very low oral bioavailability for pentapeptide; higher doses required
CYCLE
2-3x daily 5 days on / 2 days off 4-6 week cycles
BIOAVAILABILITY
~80-100% subq very low oral (~1-3%)
ACTIVE DURATION
2-3h (subjective)
STORAGE
Lyophilized powder: room temperature dry away from light. Reconstituted: refrigerate at 2-8°C use within 14-30 days
HALF-LIFE
~2h (plasma)
DURATION BREAKDOWN
Total3-4h
Onset15-30min
Come up15-30min
Peak1-2h
Offset1-2h
After effects1-2h
Duration varies by route, dose, and individual. Source: community reports.
§ 01 — EFFECTS
7 documented
Increased growth hormone release
Enhanced muscle recovery
Improved sleep quality
Increased appetite
Promotes longitudinal bone growth
Anti-catabolic effects
Minimal cortisol elevation
§ 02 — RISKS
Not approved for human use by FDA, EMA, or other major regulatory bodies
Banned by WADA as a growth hormone secretagogue
Lack of human clinical safety data for long-term use
Potential for GH-related side effects including water retention and joint pain
Risk of contamination or mislabeling in grey-market supply chain
Possible pituitary desensitization with prolonged use
§ 03 — INTERACTIONS
Interaction data not yet available for this compound.
§ 04 — SCIENCE

Ipamorelin was developed by Novo Nordisk as the first selective GH secretagogue, showing GH-releasing potency comparable to GHRP-6 in both in vitro and in vivo animal models. In rats, it dose-dependently increased longitudinal bone growth rate and body weight gain over 15 days of subcutaneous administration. In swine, it demonstrated GH release specificity without affecting ACTH or cortisol, unlike GHRP-6 and GHRP-2. Recent studies in ferrets showed it can inhibit cisplatin-induced weight loss during the delayed phase. However, human clinical trial data remain scarce; most evidence comes from animal models, and ipamorelin is not approved for human therapeutic use by major regulatory agencies. It is frequently combined with CJC-1295 in sports medicine contexts, but orthopaedic evidence is limited to murine models showing improved muscle recovery from glucocorticoid-induced atrophy.

§ 06 — SOURCES
[1]
Ipamorelin, the first selective growth hormone secretagogue
pubmed.ncbi.nlm.nih.gov ↗
[2]
Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions
pubmed.ncbi.nlm.nih.gov ↗
[3]
Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians
pubmed.ncbi.nlm.nih.gov ↗
[4]
Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance
pubmed.ncbi.nlm.nih.gov ↗
[5]
Ipamorelin, a new growth-hormone-releasing peptide, induces longitudinal bone growth in rats
pubmed.ncbi.nlm.nih.gov ↗
[6]
Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions
pubmed.ncbi.nlm.nih.gov ↗
[7]
GHS-R1a agonists anamorelin and ipamorelin inhibit cisplatin-induced weight loss in ferrets
pubmed.ncbi.nlm.nih.gov ↗
[8]
Influence of ghrelin agonist ipamorelin on hypothalamic-pituitary-testicular axis in cichlid fish
pubmed.ncbi.nlm.nih.gov ↗
Disclaimer. Protokol.wiki is an informational reference. Nothing on this site is medical advice. Compounds listed may be unapproved, unregulated, or illegal in your jurisdiction. Consult a licensed physician before use. Data compiled from peer-reviewed literature.
METHODOLOGYCONTRIBUTECONTACT